We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.
“I am delighted to welcome John to our team! His visionary leadership and innovative approach will be instrumental in driving our company forward as we continue our jounrey to be the premier provider of clinical and epidemiological services for vaccine developers worldwide.” – Thomas Verstraeten, P95 Chief Executive Officer
John joins us from his previous role as Chief Commercial Officer at Excelya Group, a contract research organization (CRO) providing full-service clinical, FSP, and resourcing solutions. Prior to this, John held leadership and business development roles in various clinical CROs including Cmed, Chiltern, Theorem Clinical and Parexel.
Please join us in extending a warm welcome to John! We are excited to have him on board and look forward to his valuable contributions to our organization’s continued success.
Stay tuned for exciting updates as we embark on this new chapter together!
Laurence De Moerlooze Joins P95 as Chief Medical Officer
P95 BV, an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO).
0 Comments